Applying Guideline-based Treatment for Patients With Renal Cell Carcinoma

Applying Guideline-based Treatment for Patients With Renal Cell Carcinoma is organized by Connect Educate Impact (CEI).

Initial Release Date: October 1, 2021
Planned Expiration Date: October 1, 2024

Description:
More than 76,000 people in the US are diagnosed each year with renal cell carcinoma (RCC). Increased approval of oral therapies and recent guideline updates both elevate the pharmacist's important role to support patients in managing their treatment. Learn about pathophysiology, assessments, diagnosis, and treatment algorithm updates so you can appropriately manage patients with RCC.

Objectives:
Upon successful completion of this application-based CPE course, pharmacists should be able to:
• List the signs, symptoms, and diagnostic and staging criteria of renal cell carcinoma
• Apply guideline-based treatment algorithms to persons with renal cell carcinoma
• Develop monitoring plans for persons with renal cell carcinoma and medications used to treat renal cell carcinoma
• Formulate evidence-based recommendations for persons with renal cell carcinoma
• Discuss the role of the pharmacy team in the patient journey for persons with renal cell carcinoma